Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on January 18, 2013. The filing reports the entry into a Material Definitive Agreement with Patheon Pharmaceuticals Inc. regarding the manufacturing of Sufentanil NanoTabs (ARX-01) for use in the Company's PCA System.
Key Financial Metrics and Agreements
The filing details specific financial obligations under the new Manufacturing Services Agreement and Amended and Restated Capital Expenditure and Equipment Agreement:
- Capital Expenditures: The Company is responsible for future facility modifications at Patheon's Cincinnati facility, with an aggregate expected cost of less than $3.5 million.
- One-Time Payment: A one-time payment of $480,000 is required to offset taxes incurred by Patheon for prior facility modifications. This payment may be reimbursed by Patheon if the Company receives FDA approval for ARX-01.
- Overhead Fee: The Company must pay a maximum annual overhead fee of $200,000 during the agreement term, which may be reduced to $0 based on annual revenues earned by Patheon.
- Purchase Commitments: The Company agreed to purchase 100% of its Product requirements for the U.S., Canada, and Mexico during the Initial Term (through December 31, 2017), and at least 80% thereafter.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the execution of the Services Agreement and Capital Agreement, which supersedes a previous Capital Expenditure and Equipment Agreement dated May 25, 2011. These agreements formalize the exclusive manufacturing relationship for the Company's lead product candidate in key North American markets.
Outlook, Risks, and Contingencies
Term and Renewal: The Initial Term extends to December 31, 2017, with automatic two-year renewals unless terminated with 18 months' prior written notice. Termination without cause is not permitted prior to the end of the Initial Term.
Termination Rights:
- The Company may terminate with 30 days' notice if regulatory actions prevent the import, export, purchase, or sale of the Product.
- Patheon may terminate with six months' notice if the Company assigns rights to a competitor.
- Either party may terminate immediately upon the bankruptcy or insolvency of the other.
Contingencies: The $480,000 one-time payment is contingent on potential reimbursement upon FDA approval of ARX-01. Pricing for bulk Product is subject to annual adjustment.
Investor Verification Checklist
- Verify the status of FDA approval for ARX-01 to determine if the $480,000 payment will be reimbursed.
- Monitor the Company's cash position to ensure it can fund the expected capital expenditures of less than $3.5 million and annual overhead fees.
- Review the full text of the Services Agreement and Capital Agreement when filed as exhibits to the Form 10-Q for the quarter ending March 31, 2013.
- Assess the risk of regulatory actions that could trigger the Company's 30-day termination right.